Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Synairgen News

    0,0565 € 0,00% +0,00 €
    08:09:38 Uhr Frankfurt aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0DK7J
    ISIN: GB00B0381Z20
    US-Symbol: SYGGF
    Typ: Aktie

    Synairgen News

    30.09.21 - GlobeNewswire
    Non-Executive Director Appointment
    Synairgen plc (‘Synairgen’ or the ‘Company’)
    30.09.21 - GlobeNewswire
    Interim results for the six months ended 30 June 2021
    Synairgen plc (‘Synairgen’ or the ‘Company’)
    24.05.21 - GlobeNewswire
    Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants
    Press release
    12.05.21 - GlobeNewswire
    Preliminary results for the year ended 31 December 2020
    Press release
    30.04.21 - GlobeNewswire
    Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial
    Press release
    15.02.21 - GlobeNewswire
    Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
    Press release
    25.01.21 - GlobeNewswire
    Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients
    Press release
    20.01.21 - GlobeNewswire
    Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta
    Press release
    13.01.21 - GlobeNewswire
    Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients
    Press release
    18.12.20 - GlobeNewswire
    COVID-19 Clinical Programme Update
    Press release
    25.07.20 - The Motley Fool
    3 positive News für die BioNTech-Aktie, AstraZeneca-Aktie und für CureVac
    Die Aktienmärkte wissen oft mehr, als wir annehmen. So stiegen die Kurse nach einem heftigen Einbruch bereits seit Mitte März 2020 bis heute fast wieder auf Vorkrisenniveau ...
    21.07.20 - The Motley Fool
    Synairgen-Aktie mit Durchbruch in der COVID-19-Behandlung
    Aktuell scheint die Verbreitung des Coronavirus erst richtig Fahrt aufzunehmen. Viele Menschen gehen jedoch davon aus, dass nach der Wirtschaftsöffnung alles wieder wie vorher ...
    20.07.20 - GlobeNewswire
    Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients
    Press release
    10.03.17 - PR Newswire
    Synairgen plc: Additional Positive Data in Lung Fibrosis
    Synairgen plc: Additional Positive Data in Lung Fibrosis PR Newswire
    10.03.17 - PR Newswire
    Synairgen plc: Additional Positive Data in Lung Fibrosis
    Synairgen plc: Additional Positive Data in Lung Fibrosis PR Newswire
    05.08.15 - PR Newswire
    Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis
    Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis PR Newswire
    05.08.15 - PR Newswire
    Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis
    Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis PR Newswire

    Newssuche

    Videos

    newspaper
    09:10 Uhr
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: UH45D5 Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »